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Abstract
Introduction The aim of this study was to describe breast tumor
subtypes by common breast cancer risk factors and to
determine correlates of subtypes using baseline data from two
pooled prospective breast cancer studies within a large health
maintenance organization.
Methods Tumor data on 2544 invasive breast cancer cases
subtyped by estrogen receptor, progesterone receptor, and
human epidermal growth factor receptor 2 (Her2) status were
obtained (1868 luminal A tumors, 294 luminal B tumors, 288
triple-negative tumors and 94 Her2-overexpressing tumors).
Demographic, reproductive and lifestyle information was
collected either in person or by mailed questionnaires. Case-
only odds ratios (ORs) and 95% confidence intervals (CIs) were
estimated using logistic regression, adjusting for age at
diagnosis, race/ethnicity, and study origin.
Results Compared with luminal A cases, luminal B cases were
more likely to be younger at diagnosis (P = 0.0001) and were
less likely to consume alcohol (OR = 0.74, 95% CI = 0.56 to
0.98), use hormone replacement therapy (HRT) (OR = 0.66,
95% CI = 0.46 to 0.94), and oral contraceptives (OR = 0.73,
95% CI = 0.55 to 0.96). Compared with luminal A cases, triple-
negative cases tended to be younger at diagnosis (P  0.0001)
and African American (OR = 3.14, 95% CI = 2.12 to 4.16),
were more likely to have not breastfed if they had parity greater
than or equal to three (OR = 1.68, 95% CI = 1.00 to 2.81), and
were more likely to be overweight (OR = 1.82, 95% CI = 1.03
to 3.24) or obese (OR = 1.97, 95% CI = 1.03 to 3.77) if
premenopausal. Her2-overexpressing cases were more likely to
be younger at diagnosis (P = 0.03) and Hispanic (OR = 2.19,
95% CI = 1.16 to 4.13) or Asian (OR = 2.02, 95% CI = 1.05 to
3.88), and less likely to use HRT (OR = 0.45, 95% CI = 0.26 to
0.79).
Conclusions These observations suggest that investigators
should consider tumor heterogeneity in associations with
traditional breast cancer risk factors. Important modifiable
lifestyle factors that may be related to the development of a
specific tumor subtype, but not all subtypes, include obesity,
breastfeeding, and alcohol consumption. Future work that will
further categorize triple-negative cases into basal and non-basal
tumors may help to elucidate these associations further.
Introduction
Among women in the USA, breast cancer remains the most
commonly diagnosed cancer, excluding skin cancers, and the
second leading cause of cancer-related death [1]. Breast can-
cer is characterized by its molecular and clinical heterogeneity.
Studies using cDNA microarrays and immunohistochemical
(IHC) markers [2-6] have classified breast cancers into five
distinct subtypes: luminal A (estrogen receptor (ER) positive
BMI: body mass index; CBCS: Carolina Breast Cancer Study; CI: confidence interval; CK: cytokeratin; EGFR: epidermal growth factor receptor; ER: 
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and/or progesterone receptor (PR) positive, human epidermal
growth factor receptor 2 (Her2) negative), luminal B (ER pos-
itive and/or PR positive, Her2 positive), Her2 overexpressing
(ER negative, PR negative, Her2 positive), basal-like (ER neg-
ative, PR negative, Her2 negative, cytokeratin (CK) 5/6 posi-
tive and/or epidermal growth factor receptor (EGFR) positive)
and normal breast-like tumors. Approximately 70% of 'triple-
negative' breast cancers (ER negative, PR negative, Her2 neg-
ative) express basal markers [7-9], resulting in the triple-nega-
tive subtype commonly being used as a surrogate marker for
the basal-like subtype.
Luminal tumors have been associated with the most favorable
prognoses, while Her2-overexpressing and basal-like tumors,
or their surrogate triple negative tumors, have been associated
with the worst prognoses [2,3,5,6,10-18]. For triple-negative
tumors, the peak risk of recurrence occurs within three years
of diagnosis, and mortality rates are increased for five years
after diagnosis [14,19]. The subtype accounts for approxi-
mately 15% of invasive breast cancers [2,4,10,11,20] and is
commonly associated with African American race
[2,10,17,20-22], younger age at diagnosis
[10,11,14,16,17,19,20,22-24], more advanced stage
[10,11,24], higher grade [2,5,9,11,14,16,17,19,21,24,25],
high mitotic indices [2,16,26], family history of breast cancer
[27], and BRCA1 mutations [23,28,29].
Although many studies have examined associations between
common breast cancer risk factors, race [30-36] and hormone
receptor status [36-41], few studies have explored the rela-
tionship between common breast cancer risk factors and the
molecular subtypes of breast cancer [22,27,42,43] [see Addi-
tional data file 1]. Therefore, we set out to describe breast
tumor subtypes by race/ethnicity and common breast cancer
risk factors and to determine correlates of breast cancer sub-
types using baseline data from two large, prospective breast
cancer survivorship studies of 2544 invasive breast cancer
cases.
Materials and methods
LACE Study
The Life After Cancer Epidemiology (LACE) Study consists of
2280 women diagnosed with invasive breast cancer between
1997 and 2000 and recruited primarily from the Kaiser Perma-
nente Northern California (KPNC) Cancer Registry (82%) and
the Utah Cancer Registry (12%). Further details on the LACE
cohort have been previously reported [44]. Briefly, eligibility
criteria included age between 18 and 70 years at enrollment;
a diagnosis of early-stage primary breast cancer (stages I  1
cm, II, or IIIA); enrollment between 11 and 39 months post-
diagnosis; having completed breast cancer treatment (except
for adjuvant hormonal therapy); free of recurrence; and no his-
tory of other cancers in the five years prior to enrollment.
Between January 2000 and April 2002, 2280 eligible women
completed baseline questionnaires via mail. The mean time
from diagnosis to enrollment was 22.8 months (range = 11.0
to 38.9 months). The study was approved by the institutional
review boards (IRB) of KPNC and the University of Utah. The
present analysis includes data from 1821 KPNC breast can-
cer patients from the LACE Study with complete breast can-
cer subtype information.
Pathways Study
The Pathways Study is a prospective cohort study actively
recruiting women diagnosed with invasive breast cancer from
the KPNC patient population since January 2006. Women are
recruited as soon after diagnosis as possible (usually within
two months), as described elsewhere [45]. Briefly, cases are
rapidly ascertained on a daily basis by automatic scanning of
electronic pathology reports with subsequent verification of
cancer diagnosis and patient notification by a medical record
analyst. Eligibility criteria include: current KPNC membership;
at least 21 years of age at diagnosis; recent diagnosis of first
primary invasive breast cancer (all stages); no prior history of
any cancer; ability to speak English, Spanish, Cantonese, or
Mandarin; and live within a 65-mile radius of a field interviewer.
In addition, a passive consent is obtained from the patient's
physician of record by an email notification stating our inten-
tion to contact the patient for study recruitment. Recruitment
is ongoing, and as of 20 October, 2008, 2212 breast cancer
patients have been enrolled via in-person interview. The mean
time from diagnosis to enrollment is 1.9 months (range = 0 to
7.3 months). Written informed consent is obtained from all
participants before they are enrolled in the study, typically at
the time of the in-person baseline interview. The study was
approved by the IRB of KPNC and all collaborating sites. In
order to make these cases comparable with those from the
LACE Study, the present analysis includes data from the first
723 women enrolled with a diagnosis of stages I  1 cm, II, or
IIIA breast cancer and having complete breast cancer subtype
data.
Data collection
Reproductive and lifestyle factors
In the mailed baseline questionnaire of the LACE Study and
during the in-person baseline interview of the Pathways Study,
participants were asked detailed information on family history
of cancer and reproductive history, including age at first full-
term pregnancy, number of biological children, breastfeeding,
and menopausal status. Additional information was collected
on smoking, alcohol use, hormone use (oral contraceptives
(OC), hormone replacement therapy (HRT)), and demograph-
ics (age at breast cancer diagnosis, race/ethnicity, household
income, education). Self-reported height and weight one year
before diagnosis (LACE) and around diagnosis (Pathways)
was obtained to calculate body mass index (BMI, kg/m2). Any
missing values were supplemented by concurrent information
from KPNC electronic medical records.Available online http://breast-cancer-research.com/content/11/3/R31
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Table 1
Distribution of demographic, reproductive, and lifestyle risk factors by race/ethnicity in the combined LACE and Pathways Studies 
(n = 2544)
White Total n = 
1943 n (%)
African American 
Total n = 155 n (%)
Asian Total n = 
189 n (%)
Hispanic Total n 
= 197 n (%)
Other Total n = 
54 n (%)
P valuea
Age at diagnosis (years) < 0.0001
< 50 389 (20.0) 43 (27.7) 61 (32.3) 67 (34.0) 13 (24.1)
50 to 64 879 (45.2) 80 (51.6) 87 (46.0) 80 (40.6) 29 (53.7)
 65 675 (34.7) 32 (20.6) 41 (21.7) 50 (25.4) 12 (22.2)
mean (± standard 
deviation)
59.8 (11.2) 56.2 (10.7) 54.8 (11.0) 55.7 (12.4) 57.7 (9.8)
Menopausal status < 0.0001
Postmenopausal 1,330 (75.6) 90 (71.4) 104 (59.1) 117 (65.4) 35 (72.9)
Premenopausal 430 (24.4) 36 (28.6) 72 (40.9) 62 (34.6) 13 (27.1)
Family history 0.001
No 1,503 (77.4) 133 (85.8) 163 (86.2) 167 (84.8) 41 (75.9)
Yes 440 (22.6) 22 (14.2) 26 (13.8) 30 (15.2) 13 (24.1)
Parity 0.006
Nulliparous 343 (17.7) 22 (14.2) 46 (24.3) 31 (15.7) 9 (16.7)
1 to 2 children 894 (46.0) 67 (43.2) 93 (49.2) 79 (40.1) 31 (57.4)
 3 children 706 (36.3) 66 (42.6) 50 (26.5) 87 (44.2) 14 (25.9)
Age at first full-term 
pregnancy (years)
< 0.0001
Nulliparous 343 (17.7) 22 (14.3) 46 (24.3) 31 (15.8) 9 (16.7)
< 26 1,020 (52.6) 113 (73.4) 61 (32.3) 119 (60.7) 28 (51.9)
 26 578 (29.8) 19 (12.3) 82 (43.4) 46 (23.5) 17 (31.5)
Lifetime duration of 
lactation
0.215
Never 908 (47.3) 92 (59.7) 81 (44.3) 91 (48.1) 25 (47.2)
0 to 3 months 279 (14.5) 19 (12.3) 31 (16.9) 25 (13.2) 8 (15.1)
 4 months 733 (38.2) 43 (27.9) 71 (38.8) 73 (38.6) 20 (37.7)
Alcohol use < 0.0001
Never 675 (39.9) 77 (67.5) 116 (75.3) 93 (62.4) 28 (57.1)
Ever 1,016 (60.1) 37 (32.5) 38 (24.7) 56 (37.6) 21 (42.9)
Smoking history (years) < 0.0001
Never 925 (48.0) 73 (47.4) 148 (78.3) 113 (57.4) 22 (40.7)
 10 269 (14.0) 17 (11.0) 13 (6.9) 33 (16.8) 6 (11.1)
11 to 19 169 (8.8) 10 (6.5) 8 (4.2) 6 (3.0) 5 (9.3)
 20 563 (29.2) 54 (35.1) 20 (10.6) 45 (22.8) 21 (38.9)
Hormone replacement 
therapy (postmenopausal 
women only)
Never 310 (23.8) 37 (42.1) 47 (45.6) 37 (32.2) 12 (34.3)
Ever 994 (76.2) 51 (57.9) 56 (54.4) 78 (67.8) 23 (65.7)
Oral contraceptive use < 0.0001Breast Cancer Research    Vol 11 No 3    Kwan et al.
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Tumor characteristics
Data on ER and PR status and Her2 expression were obtained
from medical record review and the KPNC Cancer Registry
[46] for LACE and from the KPNC Cancer Registry and other
KPNC databases for Pathways. Data are collected, coded,
and added to the KPNC Cancer Registry approximately four
months after diagnosis to allow for the completion of treat-
ment. For all breast surgical specimens, hormone receptor sta-
tus, and Her2 expression is determined by IHC at the KPNC
regional IHC laboratory and has been reported to the KPNC
Cancer Registry since January 2000. Gene expression profil-
ing studies have shown that IHC of paraffin sections is a relia-
ble surrogate for molecular classification of invasive breast
cancers [3,47-51]. Beginning in July 1999, if the IHC staining
for Her2 expression is equivocal (less than 30% strong stain-
ing, but more than 10% weak staining), then the specimen is
sent for fluorescence in situ hybridization (FISH) at the KPNC
regional cytogenetics laboratory. If the FISH score (Her2: 17
cen) is less than 2.0 [52], then the woman is classified as hav-
ing Her2-negative tumor expression; if the FISH score is
greater than 2.0, then the woman is classified as having Her2-
positive tumor expression. Results from FISH analyses are not
reported to the KPNC Cancer Registry, and are obtained
directly from the KPNC regional cytogenetics laboratory.
Covariate classification
Demographic, reproductive, and lifestyle covariates of interest
were classified as follows: age at diagnosis (< 50, 50 to 64, 
65 years), race/ethnicity (white, African American, Hispanic,
Asian, other), menopausal status (pre, post), family history of
breast cancer (no, yes), parity (nulliparous, 1 to 2,  3 chil-
dren), age at first full-term pregnancy (nulliparous, < 26,  26
years), lifetime duration of lactation (never, 0 to 3,  4 months),
alcohol use (never, ever), smoking duration (never,  10, 11 to
19,  20 years), hormone replacement therapy (HRT) among
post-menopausal women (never, ever), OC use (never, ever),
and BMI (< 25, 25 to 29,  30 kg/m2).
Outcome classification
Although the presence of basal markers can significantly
improve the prognostic value of the triple-negative phenotype
[13], for this analysis, we did not have IHC data for CK5/6 and
EGFR expression. Thus, we were unable to further classify tri-
ple-negative cases into basal-like and non-basal-like breast
tumors. Considering this limitation, the tumor subtype groups
in this analysis consisted of: ER positive and/or PR positive,
and Her2 negative (luminal A); ER positive and/or PR positive,
and Her2 positive (luminal B); ER negative, PR negative, and
Her2 negative (triple negative); ER negative, PR negative, and
Her2 positive (Her2-overexpressing).
Statistical analysis
Comparisons of demographic, reproductive, and lifestyle char-
acteristics by cohort study and race/ethnicity were conducted
using Pearson chi-square tests. Using the combined sample
size of 2544 breast cancer survivors, case-only odds ratios
(ORs) and 95% confidence intervals (CIs) were estimated
using logistic regression. The luminal A group was selected as
the referent because the majority of invasive breast cancer
cases are of this subtype. All models were adjusted for age at
diagnosis, race/ethnicity, and Pathways/LACE study origin
except when these covariates were the predictors of interest.
We also examined whether the associations between parity
and tumor subtype varied by breastfeeding and whether BMI
and tumor subtype varied by menopausal status by first gener-
ating strata-specific estimates and then including an interac-
tion term in the model to test for statistical significance. CIs not
overlapping with 1.00 or P < 0.05 were considered statisti-
cally significant.
Results
Demographic, reproductive, and lifestyle factors varied signifi-
cantly by race/ethnicity in the combined studies (Table 1).
Demographically, African Americans (mean age = 56.2 years)
and Asians (mean age = 54.8 years) were more likely to be
diagnosed at a younger age although whites were more likely
to be diagnosed at an older age (mean age = 59.8 years).
However, Asians (59.1%) were less likely to be post-meno-
pausal than whites (75.6%), African Americans (71.4%), and
other races/ethnicities (72.9%). A positive family history of
breast cancer was more common among whites (22.6%) and
other races/ethnicities (24.1%), than among the other groups.
Never 638 (33.8) 40 (26.7) 100 (55.9) 72 (37.7) 16 (30.2)
Ever 1,252 (66.2) 110 (73.3) 79 (44.1) 119 (62.3) 37 (69.8)
Body mass index (kg/m2)b < 0.0001
< 25 835 (43.4) 31 (20.0) 119 (63.3) 63 (32.5) 20 (37.0)
25 to 29 600 (31.1) 48 (31.0) 46 (24.5) 64 (33.0) 14 (25.9)
 30 491 (25.5) 76 (49.0) 23 (12.2) 67 (34.5) 20 (37.0)
a From Pearson chi-square test across racial/ethnic categories.
b Body mass index one year pre-diagnosis (LACE) and around diagnosis (Pathways).
Table 1 (Continued)
Distribution of demographic, reproductive, and lifestyle risk factors by race/ethnicity in the combined LACE and Pathways Studies 
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Reproductive history also differed markedly by race/ethnicity;
African Americans and Hispanics had more biological children
(42.6% and 44.2%, respectively) and were younger during
their first pregnancy (73.4% and 60.7%) compared with the
other races/ethnicities. Whites were more likely to have ever
consumed alcohol (60.1%) while Asians (78.3%) were more
likely to have never smoked. Among the hormonal factors,
more whites had used HRT (76.2%) compared with the other
races/ethnicities, while fewer Asians (44.1%) had used OCs
compared with the other races/ethnicities. African Americans
were more obese at diagnosis (49.0%) followed by other
races/ethnicities (37.0%) and Hispanics (34.5%). Additional
data file 2 shows the distribution of demographic, reproduc-
tive, and lifestyle factors in the LACE and Pathways Studies
separately. Overall, the two study populations were similar
demographically, yet non-similarities were apparent among
reproductive and hormonal factors, likely to be due to differ-
ences in time periods of data collection.
The distribution of breast cancer subtypes by race/ethnicity in
the combined studies is presented in Table 2. Among the
2544 invasive breast cancer cases, 1868 (73.4%) were clas-
sified as luminal A, 294 (11.6%) as luminal B, 288 (11.3%) as
triple negative, and 94 (3.7%) as Her2-overexpressing. The
distribution of race/ethnicity within each subtype compared
with all other subtypes varied significantly (P  < 0.05). The
majority of the whites (75.3%), Asians (71.4%), Hispanics
(68.5%), other (68.5%), and African Americans (59.4%) had
the luminal A tumor subtype. The Her2-overexpressing sub-
type was least common among all races/ethnicities (whites
3.1%, African Americans 3.2%, Asians 6.4%, Hispanics 6.6%,
other 5.5%). African Americans had the highest prevalence of
the triple negative subtype (28.4%) compared with the other
races/ethnicities (whites 10.5%, Asians 6.3%, Hispanics
10.7%, other 13.0%).
The associations between various demographic, reproductive,
and lifestyle factors within each subtype (luminal B, triple neg-
ative, and Her2-overexpressing) compared with luminal A are
shown in Tables 3 and 4. All case-only ORs were adjusted for
age, race/ethnicity, and Pathways/LACE study origin except
when either age at diagnosis or race/ethnicity were the main
predictors in the logistic regression model. Compared with
luminal A cases, luminal B cases were more likely to be
younger at diagnosis (OR for < 50 years = 1.83, 95% CI =
1.32 to 2.55; P = 0.0001) and were less likely to consume
alcohol (OR = 0.74, 95% CI = 0.56 to 0.98), use HRT (OR =
0.66, 95% CI = 0.46 to 0.94), and OC (OR = 0.73, 95% CI
= 0.55 to 0.96). Compared with luminal A cases, triple nega-
tive cases tended to be younger at diagnosis (OR for < 50
years = 2.78, 95% CI = 1.99 to 3.90; P  0.0001) and African
American (OR = 3.14, 95% CI = 2.12 to 4.16). Breastfeeding
for at least four months was associated with being less likely
to have a triple negative tumor, yet this association was of bor-
derline significance (OR = 0.78, 95% CI = 0.59 to 1.03).
Compared with luminal A cases, Her2-overexpressing cases
were more likely to be younger at diagnosis (P = 0.03), similar
to luminal B and triple negative cases, and less likely to use
HRT (OR = 0.49, 95% CI = 0.26 to 0.79), similar to luminal B
cases. Furthermore, Her2-overexpressing cases were more
likely to be Hispanic (OR = 2.19, 95% CI = 1.16 to 4.13) and
Asian (OR = 2.02, 95% CI = 1.05 to 3.88). The associations
between the risk factors and tumor subtypes for the individual
studies are presented in Additional data files 3 and 4. The
majority of the case-only ORs were in the same direction as
observed in the combined analysis, except for the association
between BMI and the triple-negative subtype. In the LACE
Study, triple-negative cases were more likely to have higher
Table 2
Distribution of breast cancer tumor subtypes by race/ethnicity in the combined LACE and Pathways Studies (n = 2544)
Tumor subtype White n (%) African American n (%) Asian n (%) Hispanic n (%) Other n (%) P valuea
Luminal A
(ER+ and/or PR+, Her2-)
n = 1868 (73.4)
1464 (75.3) 92 (59.4) 135 (71.4) 135 (68.5) 37 (68.5) 0.0001
Luminal B
(ER+ and/or PR+, Her2+)
n = 294 (11.6)
215 (11.1) 14 (9.0) 30 (15.9) 28 (14.2) 7 (13.0) 0.18
Triple negative
(ER-, PR-, Her2-)
n = 288 (11.3)
204 (10.5) 44 (28.4) 12 (6.3) 21 (10.7) 7 (13.0) < 0.0001
Her2 overexpressing
(ER-, PR-, Her2+)
n = 94 (3.7)
60 (3.1) 5 (3.2) 12 (6.4) 13 (6.6) 3 (5.5) 0.03
Total n = 2544 (100) 1943 (100) 155 (100) 189 (100) 197 (100) 54 (100) ---
a From Pearson chi-square test across racial/ethnic categories.
ER = estrogen receptor; Her2 = human epidermal growth receptor 2; PR = progesterone receptor; + = positive; - = negative.Breast Cancer Research    Vol 11 No 3    Kwan et al.
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Table 3
Case-only odds ratios and 95% confidence intervals from logistic regression modelsa of associations between breast cancer tumor 
subtypes and demographic, reproductive, and lifestyle risk factors, combined LACE and Pathways Studies (n = 2544)
Luminal A (comparison) Luminal Ba
n N OR 95% CI
Age at diagnosis (years)
 65 (Ref) 637 82 Ref ---
50 to 64 871 124 1.09 0.81, 1.47
< 50 355 88 1.83 1.32, 2.55
Test for trend P = 0.0001
Race/ethnicity
White (Ref) 1464 215 Ref ---
African American 92 14 0.97 0.54, 1.74
Hispanic 135 28 1.32 0.85, 2.04
Asian 135 30 1.38 0.90, 2.12
Other 37 7 1.29 0.56, 2.94
Menopausal status ---
Postmenopausal (Ref) 1283 173 Ref
Premenopausal 406 95 1.32 0.87, 2.00
Family history
No (Ref) 1453 245 Ref ---
Yes 410 49 0.74 0.53, 1.02
Age at first full-term pregnancy (years)
Nulliparous (Ref) 335 51 Ref ---
< 26 959 158 1.25 0.88, 1.78
 26 567 85 1.04 0.72, 1.52
Parity
Nulliparous (Ref) 335 51 Ref ---
1 to 2 children 837 150 1.24 0.88, 1.76
 3 children 691 93 1.03 0.70, 1.50
Lifetime duration of breastfeeding
Never (Ref) 871 135 Ref ---
0 to 3 months 255 50 1.31 0.92, 1.88
 4 months 711 100 0.86 0.65, 1.14
Parity among never breastfedb
Nulliparous (Ref) 321 50 Ref ---
1 to 2 children 326 59 1.38 (0.89, 2.13)
 3 children 224 26 1.01 (0.58, 1.76)
Parity among 0 to 3 months breastfedb
1 to 2 children (Ref) 144 33 Ref ---
 3 children 108 17 0.90 (0.45, 1.77)
Parity among  4 months breastfedbAvailable online http://breast-cancer-research.com/content/11/3/R31
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BMI while in the Pathways Study the opposite trend was
observed, although these effect measures were not statisti-
cally significant.
For the subgroup analyses, among non-breastfeeding cases,
parity of at least three children was associated with a statisti-
cally significant increased likelihood of having a triple-negative
tumor (OR = 1.68; 95% CI = 1.00 to 2.81) and a Her2-over-
expressing tumor (OR = 3.03; 95% CI = 1.27 to 7.23) com-
pared with luminal A. In contrast, no differential associations of
breastfeeding and parity were observed among luminal B
cases. All P values for interaction of parity by breastfeeding
were not statistically significant. As for the effect of BMI by
menopausal status, premenopausal triple-negative and Her2-
overexpressing cases were more likely to be overweight (triple
negative: OR = 1.82, 95% CI = 1.03 to 3.24; Her2-overex-
pressing: OR = 2.15, 95% CI = 0.70 to 6.58) or obese (triple
negative: OR = 1.97, 95% CI = 1.03 to 3.77; Her2-overex-
pressing: OR = 2.51, 95% CI = 0.74 to 8.51) at diagnosis, yet
the effect measures for Her2-overexpressing tumors were not
1 to 2 children (Ref) 358 56 Ref ---
 3 children 352 44 0.84 (0.54, 1.32)
Alcohol use
Never (Ref) 709 131 Ref ---
Ever 880 119 0.74 0.56, 0.98
Smoking history
Never (Ref) 921 163 Ref ---
 10 251 39 0.86 0.59, 1.27
11 to 19 147 22 0.93 0.57, 1.51
 20 531 68 0.80 0.59, 1.09
Hormone replacement therapy (postmenopausal only)
Never (Ref) 314 55 Ref ---
Ever 943 114 0.66 0.46, 0.94
Oral contraceptive use
Never (Ref) 647 110 Ref ---
Ever 1160 172 0.73 0.55, 0.96
BMI (kg/m2)c
< 25 (Ref) 785 134 Ref ---
25 to 29 563 79 0.92 0.67, 1.24
 30 500 77 1.03 0.75, 1.41
BMI (kg/m2) among premenopausalb
< 25 (Ref) 223 50 Ref ---
25 to 29 99 21 1.11 0.62, 2.00
 30 81 24 1.68 0.92, 3.07
BMI (kg/m2) among postmenopausalb
< 25 (Ref) 480 67 Ref ---
25 to 29 422 52 0.90 0.61, 1.33
 30 372 50 0.99 0.66, 1.47
a Adjusted for age at diagnosis, race/ethnicity, and Pathways/LACE study origin except in models with age at diagnosis or race/ethnicity as main 
predictors.
b P for interaction not statistically significant (P > 0.05) in any tumor subtype model.
c BMI = body mass index one year pre-diagnosis (LACE) and around diagnosis (Pathways).
CI = confidence interval; OR = odds ratio.
Table 3 (Continued)
Case-only odds ratios and 95% confidence intervals from logistic regression modelsa of associations between breast cancer tumor 
subtypes and demographic, reproductive, and lifestyle risk factors, combined LACE and Pathways Studies (n = 2544)Breast Cancer Research    Vol 11 No 3    Kwan et al.
Page 8 of 13
(page number not for citation purposes)
Table 4
Case-only odds ratios and 95% confidence intervals from logistic regression modelsa of associations between breast cancer tumor 
subtypes and demographic, reproductive, and lifestyle risk factors, combined LACE and Pathways Studies (n = 2544)
Luminal A (comparison) Triple negativea HER2-overexpressinga
n n OR 95% CI n OR 95% CI
Age at diagnosis (years)
 65 (Ref) 637 68 Ref --- 23 Ref ---
50 to 64 871 115 1.99 0.85, 1.62 45 1.39 0.83, 2.32
< 50 355 105 2.78 1.99, 3.90 25 1.75 0.97, 3.15
Test for trend P  0.0001 P = 0.03
Race/ethnicity
White (Ref) 1464 204 Ref --- 60 Ref ---
African American 92 44 3.14 2.12, 4.66 5 1.25 0.49, 3.21
Hispanic 135 21 0.93 0.57, 1.53 13 2.19 1.16, 4.13
Asian 135 12 0.53 0.28, 0.97 12 2.02 1.05, 3.88
Other 37 7 1.28 0.56, 2.94 3 1.95 0.58, 6.52
Menopausal status
Postmenopausal (Ref) 1283 163 Ref --- 57 Ref ---
Premenopausal 406 91 0.84 0.55, 1.27 21 0.65 0.31, 1.33
Family history
No (Ref) 1453 229 Ref --- 80 Ref ---
Yes 410 59 0.95 0.69, 1.29 13 0.62 0.34, 1.13
Age at first full-term pregnancy (years)
Nulliparous (Ref) 335 52 Ref --- 13 Ref ---
< 26 959 163 1.28 0.90, 1.82 61 2.02 1.07, 3.80
 26 567 72 0.93 0.63, 1.38 18 0.86 0.42, 1.79
Parity
Nulliparous (Ref) 335 52 Ref --- 13 Ref ---
1 to 2 children 837 137 1.11 0.78, 1.58 40 1.30 0.68, 2.47
 3 children 691 99 1.18 0.81, 1.72 40 1.82 0.94, 3.53
Lifetime duration of breastfeeding
Never (Ref) 871 148 Ref --- 43 Ref ---
0 to 3 months 255 41 1.04 0.71, 1.52 16 1.29 0.71, 2.35
 4 months 711 97 0.78 0.59, 1.03 32 0.86 0.54, 1.38
Parity among never breastfedb
Nulliparous (Ref) 321 50 Ref --- 12 Ref ---
1 to 2 children 326 59 1.34 (0.87, 2.08) 15 1.52 (0.68, 3.41)
 3 children 224 39 1.68 (1.00, 2.81) 16 3.03 (1.27, 7.23)
Parity among 0 to 3 months breastfedb
1 to 2 children (Ref) 144 25 Ref --- 9 Ref ---
 3 children 108 16 1.16 (0.53, 2.56) 7 1.82 (0.57, 5.80)
Parity among  4 months breastfedbAvailable online http://breast-cancer-research.com/content/11/3/R31
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statistically significant. Among luminal A cases, these associa-
tions were not observed. All P values for interaction of BMI by
menopausal status were not statistically significant.
Discussion
In a pooled analysis of 2544 breast cancer cases using data
from two prospective cohort studies housed within a large
health maintenance organization, associations between breast
cancer subtypes and various demographic, reproductive, and
lifestyle factors were examined. In case-case analyses with the
luminal A cases as the reference group, luminal B cases were
more likely to be younger at diagnosis and were less likely to
consume alcohol, use HRT, and OCs. Triple-negative cases
tended to be younger at diagnosis and African American, and
were more likely to be overweight and/or obese at diagnosis if
premenopausal. Women with triple-negative tumors were also
less likely to breastfeed for longer periods, and were more
likely to not breastfeed if they had at least three children. Her2-
overexpressing cases were more likely to be younger at diag-
nosis and Hispanic or Asian, and less likely to use HRT. We
1 to 2 children (Ref) 358 52 Ref --- 14 Ref ---
 3 children 352 44 0.99 (0.63, 1.55) 17 1.23 (0.57, 2.66)
Alcohol use
Never (Ref) 709 110 Ref --- 39 Ref ---
Ever 880 129 0.98 0.73, 1.30 40 0.94 0.59, 1.50
Smoking history
Never (Ref) 921 146 Ref --- 51 Ref ---
 10 251 41 0.95 0.65, 1.40 7 0.51 0.23, 1.14
11 to 19 147 21 0.89 0.54, 1.47 8 1.17 0.54, 2.56
 20 531 78 0.98 0.72, 1.34 26 1.05 0.63, 1.73
Hormone replacement therapy (postmenopausal only)
Never (Ref) 314 50 Ref --- 24 Ref ---
Ever 943 112 0.83 0.57, 1.20 33 0.45 0.26, 0.79
Oral contraceptive use
Never (Ref) 647 80 Ref --- 29 Ref ---
Ever 1160 202 0.97 0.72, 1.31 63 1.12 0.69, 1.83
BMI (kg/m2)c
< 25 (Ref) 785 110 Ref --- 39 Ref ---
25 to 29 563 99 1.33 0.98, 1.81 31 1.21 0.74, 1.99
 30 500 77 1.04 0.75, 1.45 23 1.03 0.59, 1.78
BMI (kg/m2) among premenopausalb
< 25 (Ref) 223 39 Ref --- 7 Ref ---
25 to 29 99 28 1.82 1.03, 3.24 7 2.15 0.70, 6.58
 30 81 23 1.97 1.03, 3.77 7 2.51 0.74, 8.51
BMI (kg/m2) among postmenopausalb
< 25 (Ref) 480 59 Ref --- 25 Ref ---
25 to 29 422 60 1.08 0.73, 1.59 18 0.86 0.46, 1.61
 30 372 43 0.76 0.49, 1.17 14 0.76 0.38, 1.51
a Adjusted for age at diagnosis, race/ethnicity, and Pathways/LACE study origin except in models with age at diagnosis or race/ethnicity as main 
predictors.
b P for interaction not statistically significant (P > 0.05) in any tumor subtype model.
c BMI, body mass index one year pre-diagnosis (LACE) and around diagnosis (Pathways).
CI = confidence interval; HER2 = human epidermal growth receptor 2; OR = odds ratio.
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also found that these cases were more likely to be women with
at least three children and no history of breastfeeding. These
case-case observations suggest that heterogeneity in associ-
ations with traditional breast cancer risk factors exists by
tumor subtype.
Several studies have assessed risk factor profiles of tumor
subtypes, including the Carolina Breast Cancer Study
(CBCS; n = 1424 in situ and invasive cases) [22], the Polish
Breast Cancer Study (PBCS; 804 invasive cases) [27], and a
pooled study of two Washington State (WS) case-control
studies (n = 1023 invasive cases) [42,43] [see Additional data
file 1]. The CBCS and PBCS were able to classify their triple-
negative cases into basal-like and unclassified using CK5/6
and EGFR IHC expression data while the WS study did not do
so. The CBCS performed case-case and case-control analy-
ses while the PBCS and WS study conducted case-control
analyses only. Although we were unable to further classify tri-
ple-negative cases into basal-like and unclassified, similar to
the results of the CBCS (case-case analysis) and PBCS
(case-control analysis) for basal-like cases, our triple-negative
cases were more likely to be younger at diagnosis and African
American. We also observed that premenopausal triple-nega-
tive cases tended to have higher BMI, which was in agreement
with the basal-like cases in the CBCS but not the PBCS, the
latter of which found no association. Interestingly, the WS
study (case-control analysis) reported a suggestive increased
risk of triple-negative tumors with increasing BMI among
women currently using hormone therapy [42], yet we did not
see any such association in our study. The WS study (case-
control analysis) also reported that breastfeeding for at least
six months was related to a reduced risk of triple-negative
tumors [43]. Similarly, both the CBCS (case-case analysis)
and our study found suggestive associations of shorter dura-
tion of breastfeeding (less than four months) with being more
likely to have a triple-negative tumor. Furthermore, both studies
observed a strong positive association for triple-negative
cases (basal-like cases for CBCS) among women who had
higher parity and never breastfed; the CBCS reported a case-
only OR for parity of at least three children and no breastfeed-
ing as 1.9 (95% CI = 1.1 to 3.4) compared with luminal A
cases. The PBCS (case-control analysis) did not present data
on the impact of breastfeeding on tumor subtypes.
As for luminal B and Her2-overexpressing cases, our results
are in agreement with those of the CBCS that luminal B and
Her2-overexpressing cases tended to be younger than luminal
A cases. In contrast to the CBCS results, we observed that
these cases were less likely to use HRT although luminal B
cases were less likely to consume alcohol. No associations
with these factors were observed in the PBCS, and the WS
study did not examine luminal tumors separately by luminal A
and luminal B subtype. We found that Her2-overexpressing
cases were more likely to be Hispanic or Asian, but not African
American, an observation which was not seen in any of the
other studies. In fact, the CBCS, comprised of only whites and
African Americans, reported that Her2-overexpressing cases
were slightly more likely to be African American. Finally, we
observed that Her2-overexpressing cases were more likely to
be women who had at least three children and had not breast-
fed, an association not seen in the CBCS.
Although our results tend to be in agreement with those of
other studies, limitations of our study should be discussed.
Only case-case comparisons were conducted, and it must be
emphasized that the associations reported here are all in ref-
erence to risk of having a luminal A tumor subtype and should
not be extended to risk of having invasive breast cancer. Case-
case analyses among tumor subtypes are a useful exploratory
tool to examine etiologic heterogeneity between the subtypes
[53]. As previously mentioned, we have no data on CK5/6 and
EGFR tumor markers to further classify triple-negative tumors
into basal-like and unclassified. However, with additional fund-
ing, we plan to conduct these additional IHC assays in triple
negative cases. Also, as there were a limited number of Her2-
overexpressing tumors (n = 94; 3.7%), results concerning this
subtype should be interpreted with caution. Finally, although
our large study population of 2544 women diagnosed with
invasive breast cancer was more ethnically diverse (76.6%
white, 6.1% African American, 7.8% Hispanic, 7.4% Asian,
2.1% other) than other studies that have examined breast can-
cer risk factors among tumor subtypes, unlike the CBCS, we
were unable to further examine risk factors by white and Afri-
can American race/ethnicity due to limited numbers. Our find-
ings, especially those regarding Hispanic and Asian
differences, should be replicated in other population-based
studies.
Conclusions
In summary, using a case-case analysis to assess the associ-
ations between traditional breast cancer risk factors and
breast cancer subtypes (luminal A, luminal B, triple negative,
and Her2-overexpressing), we observed significant heteroge-
neity of associations by tumor subtype. These varying associ-
ations by subtype lend further support to the growing evidence
base that breast cancer is a heterogeneous disease defined
by ER, PR, and Her2 expression with distinct etiologic path-
ways and prognoses. Future research should focus on refine-
ment of tumor subtypes into more homogenous subgroups in
order to best elucidate how risk factors may vary by subtype.
Important modifiable factors that may be related to the devel-
opment of specific tumor subtypes include obesity and possi-
bly breastfeeding (triple negative) and alcohol consumption
(luminal B), yet no clear modifiable risk factor profile was
apparent for Her2-overexpressing subtypes due to a limited
sample size. Given this information, public health programs
aimed towards achieving a healthy weight and promoting
breastfeeding might reduce the number of poor prognostic tri-
ple negative tumors among all breast cancer cases, especially
the high-risk African American group.Available online http://breast-cancer-research.com/content/11/3/R31
Page 11 of 13
(page number not for citation purposes)
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MLK contributed to study conception and design, and acqui-
sition, analysis, and interpretation of data; and drafted and
revised the manuscript critically for important intellectual con-
tent. LHK and BJC contributed to study conception and
design, and acquisition, analysis, and interpretation of data;
and revised the manuscript critically for important intellectual
content. EW contributed to analysis and interpretation of data;
and revised the manuscript critically for important intellectual
content. BM contributed to study conception and design; and
revised the manuscript critically for important intellectual con-
tent. SEK contributed to analysis and interpretation of data;
and revised the manuscript critically for important intellectual
content. RSF contributed to acquisition of data; and revised
the manuscript critically for important intellectual content.
MML contributed to analysis and interpretation of data; and
revised the manuscript critically for important intellectual con-
tent. CBA contributed to analysis and interpretation of data;
and revised the manuscript critically for important intellectual
content. All authors read and approved the final manuscript.
Additional files
Acknowledgements
The LACE Study was funded by the National Cancer Institute (R01 
CA80027) and by the Utah Cancer Registry (N01 PC67000), with addi-
tional support from the State of Utah Department of Health. The Path-
ways Study was funded by the National Cancer Institute (R01 
CA105274, R01 CA124924), the Department of Defense 
(BC043120), and the American Cancer Society (RSG-06-209-01-LR). 
We thank all LACE and Pathways Study participants, as well as the 
office and field staff. We acknowledge the technical assistance of Dr Xu 
Li of the KPNC Cytogenetics Laboratory and the programming assist-
ance of Isaac Joshua Ergas at Kaiser Permanente, Division of Research. 
The contents of this manuscript are solely the responsibility of the 
authors and do not necessarily represent the official views of the funding 
agencies.
References
1. American Cancer Society: Cancer facts and figures 2008.
Atlanta: American Cancer Society; 2008. 
2. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway
K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL,
Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Mil-
likan RC: Race, breast cancer subtypes, and survival in the
Carolina Breast Cancer Study.  JAMA 2006, 295:2492-2502.
3. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hern-
andez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA,
Ragaz J, Gown AM, Gilks CB, Rijn M van de, Perou CM: Immuno-
histochemical and clinical characterization of the basal-like
subtype of invasive breast carcinoma.  Clin Cancer Res 2004,
10:5367-5374.
4. Perou CM, Sorlie T, Eisen MB, Rijn M van de, Jeffrey SS, Rees CA,
Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamen-
schikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL,
Brown PO, Botstein D: Molecular portraits of human breast
tumours.  Nature 2000, 406:747-752.
5. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson
JF, Blamey RW, Macmillan D, Ellis IO: Basal phenotype identifies
a poor prognostic subgroup of breast cancer of clinical impor-
tance.  Eur J Cancer 2006, 42:3149-3156.
6. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H,
Hastie T, Eisen MB, Rijn M van de, Jeffrey SS, Thorsen T, Quist H,
Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-
Dale AL: Gene expression patterns of breast carcinomas dis-
tinguish tumor subclasses with clinical implications.  Proc Natl
Acad Sci USA 2001, 98:10869-10874.
7. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P,
Birnbaum D: How basal are triple-negative breast cancers?  Int
J Cancer 2008, 123:236-240.
8. Bidard FC, Conforti R, Boulet T, Michiels S, Delaloge S, Andre F:
Does triple-negative phenotype accurately identify basal-like
tumour? An immunohistochemical analysis based on 143 'tri-
ple-negative' breast cancers.  Ann Oncol 2007, 18:1285-1286.
9. Tan DS, Marchio C, Jones RL, Savage K, Smith IE, Dowsett M,
Reis-Filho JS: Triple negative breast cancer: molecular profiling
and prognostic impact in adjuvant anthracycline-treated
patients.  Breast Cancer Res Treat 2008, 111:27-44.
The following Additional files are available online:
Additional file 1
A word file containing a table that lists previous studies 
that have examined associations between common 
breast cancer risk factors and breast cancer tumor 
subtypes.
See http://www.biomedcentral.com/content/
supplementary/bcr2261-S1.doc
Additional file 2
A word file containing a table that lists the distribution of 
demographic, reproductive, and lifestyle risk factors in 
the LACE and Pathways studies individually and 
combined (n = 2544).
See http://www.biomedcentral.com/content/
supplementary/bcr2261-S2.doc
Additional file 3
A word file containing a table that lists case-only odds 
ratios and 95% confidence intervals from logistic 
regression models of associations between breast 
cancer tumor subtypes and demographic, reproductive, 
and lifestyle risk factors, LACE study (n = 1821).
See http://www.biomedcentral.com/content/
supplementary/bcr2261-S3.doc
Additional file 4
A word file containing a table that shows case-only odds 
ratios and 95% confidence intervals from logistic 
regression models of associations between breast 
cancer tumor subtypes and demographic, reproductive, 
and lifestyle risk factors, Pathways study (n = 723).
See http://www.biomedcentral.com/content/
supplementary/bcr2261-S4.docBreast Cancer Research    Vol 11 No 3    Kwan et al.
Page 12 of 13
(page number not for citation purposes)
10. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descrip-
tive analysis of estrogen receptor (ER)-negative, progesterone
receptor (PR)-negative, and HER2-negative invasive breast
cancer, the so-called triple-negative phenotype: a population-
based study from the California cancer Registry.  Cancer 2007,
109:1721-1728.
11. Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V: The role
of human epidermal growth factor receptor 2 in the survival of
women with estrogen and progesterone receptor-negative,
invasive breast cancer: the California Cancer Registry, 1999–
2004.  Cancer 2008, 112:737-747.
12. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila
DW, Sartor CI, Graham ML, Perou CM: The triple negative para-
dox: primary tumor chemosensitivity of breast cancer sub-
types.  Clin Cancer Res 2007, 13:2329-2334.
13. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK,
Perou CM, Nielsen TO: Basal-like breast cancer defined by five
biomarkers has superior prognostic value than triple-negative
phenotype.  Clin Cancer Res 2008, 14:1368-1376.
14. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA,
Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast
cancer: clinical features and patterns of recurrence.  Clin Can-
cer Res 2007, 13:4429-4434.
15. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D,
Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler
L: Molecular subtypes of breast cancer in relation to paclitaxel
response and outcomes in women with metastatic disease:
results from CALGB 9342.  Breast Cancer Res 2006, 8:R66.
16. Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM,
Makambi KH, Adams-Campbell L, Frederick WA: Molecular
breast cancer subtypes in premenopausal and postmenopau-
sal African-American women: age-specific prevalence and
survival.  J Surg Res 2007, 143:109-118.
17. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Braw-
ley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW: Race and
triple negative threats to breast cancer survival: a population-
based study in Atlanta, GA.  Breast Cancer Res Treat 2009,
113:357-370.
18. Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Aki-
yama F, Kinoshita T, Takei H, Takahashi K, Ikeda M, Nakashima K:
The prevalence of intrinsic subtypes and prognosis in breast
cancer patients of different races.  Breast 2007, 16(Suppl
2):S72-77.
19. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC,
Akslen LA, Nielsen TO, Foulkes WD: Use of immunohistochem-
ical markers can refine prognosis in triple negative breast can-
cer.  BMC Cancer 2007, 7:134.
20. Stark A, Kapke A, Schultz D, Brown R, Linden M, Raju U:
Advanced stages and poorly differentiated grade are associ-
ated with an increased risk of HER2/neu positive breast carci-
noma only in White women: findings from a prospective cohort
study of African-American and White-American women.  Breast
Cancer Res Treat 2008, 107:405-414.
21. Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL: Early onset of
breast cancer in a group of British black women.  Br J Cancer
2008, 98:277-281.
22. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Smith
LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy
C, Carey L, Earp HS, Perou CM: Epidemiology of basal-like
breast cancer.  Breast Cancer Res Treat 2008, 109:123-139.
23. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J,
Harris L, Hait W, Toppmeyer D: Locoregional relapse and dis-
tant metastasis in conservatively managed triple negative
early-stage breast cancer.  J Clin Oncol 2006, 24:5652-5657.
24. Lund MJ, Butler EN, Bumpers HL, Okoli J, Rizzo M, Hatchett N,
Green VL, Brawley OW, Oprea-Ilies GM, Gabram SG: High prev-
alence of triple-negative tumors in an urban cancer center.
Cancer 2008, 113:608-615.
25. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P,
Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP: Differ-
ences in breast carcinoma characteristics in newly diagnosed
African-American and Caucasian patients: a single-institution
compilation compared with the National Cancer Institute's
Surveillance, Epidemiology, and End Results database.  Can-
cer 2007, 110:876-884.
26. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore
DT, Perou CM: Phenotypic evaluation of the basal-like subtype
of invasive breast carcinoma.  Mod Pathol 2006, 19:264-271.
27. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA,
Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N,
Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkie-
wicz G, Ligaj M, Lukaszek S, Kordek R, Garcia-Closas M: Differ-
ences in risk factors for breast cancer molecular subtypes in a
population-based study.  Cancer Epidemiol Biomarkers Prev
2007, 16:439-443.
28. Parikh RR, Yang Q, Higgins SA, Haffty BG: Outcomes in young
women with breast cancer of triple-negative phenotype: the
prognostic significance of CK19 expression.  Int J Radiat Oncol
Biol Phys 2008, 70:35-42.
29. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng
S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning
PE, Brown PO, Borresen-Dale AL, Botstein D: Repeated obser-
vation of breast tumor subtypes in independent gene expres-
sion data sets.  Proc Natl Acad Sci USA 2003, 100:8418-8423.
30. Brinton LA, Benichou J, Gammon MD, Brogan DR, Coates R, Sch-
oenberg JB: Ethnicity and variation in breast cancer incidence.
Int J Cancer 1997, 73:349-355.
31. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane
D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, Adams-
Campbell LL, Prentice R: Ethnicity and breast cancer: factors
influencing differences in incidence and outcome.  J Natl Can-
cer Inst 2005, 97:439-448.
32. Hall IJ, Moorman PG, Millikan RC, Newman B: Comparative anal-
ysis of breast cancer risk factors among African-American
women and White women.  Am J Epidemiol 2005, 161:40-51.
33. Mayberry RM, Stoddard-Wright C: Breast cancer risk factors
among black women and white women: similarities and differ-
ences.  Am J Epidemiol 1992, 136:1445-1456.
34. Moorman PG, Millikan RC, Newman B: Oral contraceptives and
breast cancer among African-american women and white
women.  J Natl Med Assoc 2001, 93:329-334.
35. Palmer JR, Wise LA, Horton NJ, Adams-Campbell LL, Rosenberg
L: Dual effect of parity on breast cancer risk in African-Ameri-
can women.  J Natl Cancer Inst 2003, 95:478-483.
36. Ursin G, Bernstein L, Wang Y, Lord SJ, Deapen D, Liff JM, Norman
SA, Weiss LK, Daling JR, Marchbanks PA, Malone KE, Folger SG,
McDonald JA, Burkman RT, Simon MS, Strom BL, Spirtas R:
Reproductive factors and risk of breast carcinoma in a study of
white and African-American women.  Cancer 2004,
101:353-362.
37. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE:
Risk factors for breast cancer according to estrogen and pro-
gesterone receptor status.  J Natl Cancer Inst 2004,
96:218-228.
38. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moor-
man PG: Hormone-related factors and risk of breast cancer in
relation to estrogen receptor and progesterone receptor sta-
tus.  Am J Epidemiol 2000, 151:703-714.
39. Lord SJ, Bernstein L, Johnson KA, Malone KE, McDonald JA,
Marchbanks PA, Simon MS, Strom BL, Press MF, Folger SG,
Burkman RT, Deapen D, Spirtas R, Ursin G: Breast cancer risk
and hormone receptor status in older women by parity, age of
first birth, and breastfeeding: a case-control study.  Cancer
Epidemiol Biomarkers Prev 2008, 17:1723-1730.
40. Ma H, Bernstein L, Pike MC, Ursin G: Reproductive factors and
breast cancer risk according to joint estrogen and progester-
one receptor status: a meta-analysis of epidemiological stud-
ies.  Breast Cancer Res 2006, 8:R43.
41. Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi
LR, Folsom AR: Progesterone and estrogen receptors and
mammary neoplasia in the Iowa Women's Health Study: how
many kinds of breast cancer are there?  Cancer Epidemiol
Biomarkers Prev 1995, 4:319-326.
42. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI: Body size and
risk of luminal, HER2-overexpressing, and triple-negative
breast cancer in postmenopausal women.  Cancer Epidemiol
Biomarkers Prev 2008.
43. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI: Reproductive
and hormonal risk factors for postmenopausal luminal, HER-
2-overexpressing, and triple-negative breast cancer.  Cancer
2008, 113:1521-1526.Available online http://breast-cancer-research.com/content/11/3/R31
Page 13 of 13
(page number not for citation purposes)
44. Caan B, Sternfeld B, Gunderson E, Coates A, Quesenberry C,
Slattery ML: Life After Cancer Epidemiology (LACE) Study: a
cohort of early stage breast cancer survivors (United States).
Cancer Causes Control 2005, 16:545-556.
45. Kushi LH, Kwan ML, Lee MM, Ambrosone CB: Lifestyle factors
and survival in women with breast cancer.  J Nutr 2007,
137:236S-242S.
46. Oehrli MD, Quesenberry CP, Leyden W: 2006 annual report on
trends, incidence, and outcomes.  Kaiser Permanente, Northern
California Cancer Registry; 2006. 
47. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson
JF, Macmillan D, Blamey RW, Ellis IO: High-throughput protein
expression analysis using tissue microarray technology of a
large well-characterised series identifies biologically distinct
classes of breast cancer confirming recent cDNA expression
analyses.  Int J Cancer 2005, 116:340-350.
48. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Rob-
ertson JF, Nicholson RI, Ellis IO: Expression of luminal and basal
cytokeratins in human breast carcinoma.  J Pathol 2004,
203:661-671.
49. Brenton JD, Carey LA, Ahmed AA, Caldas C: Molecular classifi-
cation and molecular forecasting of breast cancer: ready for
clinical application?  J Clin Oncol 2005, 23:7350-7360.
50. Rijn M van de, Perou CM, Tibshirani R, Haas P, Kallioniemi O,
Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F,
Dieterich H, Seitz R, Ross D, Botstein D, Brown P: Expression of
cytokeratins 17 and 5 identifies a group of breast carcinomas
with poor clinical outcome.  Am J Pathol 2002, 161:1991-1996.
51. Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz
AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC: Comparison
of molecular phenotypes of ductal carcinoma in situ and inva-
sive breast cancer.  Breast Cancer Res 2008, 10:R67.
52. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC,
Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A,
McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A,
Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M,
Wheeler TM, Hayes DF, American Society of Clinical Oncology,
College of American Pathologists: American Society of Clinical
Oncology/College of American Pathologists guideline recom-
mendations for human epidermal growth factor receptor 2
testing in breast cancer.  J Clin Oncol 2007, 25:118-145.
53. Begg CB, Zhang ZF: Statistical analysis of molecular epidemi-
ology studies employing case-series.  Cancer Epidemiol
Biomarkers Prev 1994, 3:173-175.